News

Biopharma news, November 11, 2026

The most important drug and company news of November 11, 2026, ranked, each linked to its Gosset profiles.

  1. M&A

    AstraZeneca buys bacterial vaccine biotech Omniose after research tie-up

    AstraZeneca acquired Omniose, a preclinical company, on undisclosed terms rather than renewing their bacterial vaccine collaboration. Omniose's platform makes and joins conjugate vaccine parts within engineered bacterial cells. Its candidates have yet to reach human testing.

    Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

  2. Approval

    FDA clears Abbisko's pimicotinib, sold by Merck KGaA, for tenosynovial giant cell tumor

    US regulators approved PIMJETMI, a once-a-day oral CSF-1R inhibitor, for adults with symptomatic TGCT where an operation could leave them worse off. In the phase 3 MANEUVER study, 56% responded by week 25 compared with 3% on placebo. The label carries liver-injury warnings and requires blood-test monitoring; Merck KGaA holds global marketing rights.

    Source types: Press release · SEC/exchange filing. Sources are available to Gosset users. Log in to see them.

  3. Safety action

    FDA adds rare optic nerve risk to warnings for all GLP-1 drugs

    The FDA asked makers of GLP-1 receptor agonists to add NAION, a rare optic nerve disorder that can permanently impair sight, to label warnings. A pooled review of 126 trials found 10 possible cases on treatment and five on control, and causality remains unproven. Shares in Novo Nordisk and Eli Lilly climbed, as no boxed warning or prescribing limit was imposed.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

  4. Pivotal readout

    Lilly's Taltz plus Zepbound beats Taltz alone at one year in obese psoriatic arthritis

    In the 271-patient TOGETHER-PsA trial, 43.7% on the combination reached ACR50 at week 52 against 15.7% on ixekizumab alone. The week-36 primary goal, ACR50 plus at least 10% weight loss, was met by 31.7% versus 0.8%. The one-year results are exploratory, and side effects matched those already known for each drug.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  5. Pivotal readout

    Amgen's dazodalibep cuts Sjogren's disease activity in phase 3 OASIZ-301

    Both dosing schedules of dazodalibep beat placebo on systemic disease activity at week 48 in the 648-patient OASIZ-301 trial. The 1,500 mg monthly regimen also eased patient-reported dryness. Amgen will show full data at ACR Convergence 2026 and has further phase 3 and extension studies running.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  6. Pivotal readout

    BrightGene's BGM0504 meets goals in two Chinese phase 3 type 2 diabetes trials

    Across two phase 3 studies in 780 Chinese adults, the GLP-1/GIP agonist BGM0504 hit its primary and key secondary endpoints. After 32 weeks, 10 mg lowered HbA1c by 2.6 points against 0.51 on placebo, and by 2.41 against 1.95 with semaglutide. BrightGene plans a diabetes filing in China, where it already has an obesity application pending.

    Source types: SEC/exchange filing. Sources are available to Gosset users. Log in to see them.

  7. Pivotal readout

    Beam's base-edited risto-cel hits main goal in sickle cell study, BLA eyed for year-end

    At a prespecified interim look, the BEACON trial of BEAM-101 met its efficacy endpoint of at least 12 months without severe vaso-occlusive crises and all safety endpoints; response rates were not disclosed. Of 49 treated patients, 31 had enough follow-up. Beam aims to file a US biologics application as soon as the end of 2026.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  8. Financing

    VectorY Therapeutics secures EUR 74.5 million for vectorized antibody pipeline

    VectorY Therapeutics raised EUR 74.5 million, about $83.5 million, from a mix of returning and first-time backers. The money funds its ALS candidate VTx-002 to final results from PIONEER-ALS, a phase 1/2 trial now enlarged to 36 patients from 12, and also supports the Huntington's program VTx-003.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  9. Pivotal readout

    BMS reports 56-week SCOUT-HCM data for mavacamten in adolescents with obstructive HCM

    In the phase 3 SCOUT-HCM study of teenagers with symptomatic obstructive hypertrophic cardiomyopathy, those on mavacamten from the start saw the provoked outflow gradient drop by 48.1 mmHg on average. No patient's ejection fraction fell below 50%. The pediatric use is approved in the US but not in China, and more data are due at the AHA meeting.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  10. Financing

    PepGen launches $125 million stock offering to fund clinical programs

    PepGen, which develops oligonucleotide therapies for rare genetic diseases, proposed selling $125 million of shares, with pre-funded warrants for some investors. Underwriters would get a 30-day option on another $18.75 million. Proceeds are earmarked for clinical development and general corporate needs.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call